Physicians and researchers at the OSU Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute are continually seeking answers to questions about endocrine cancers.  For example:

  • A study recently published in the Journal of Clinical Endocrinology & Metabolism by Richard Kloos, MD, and other OSU CCC-James researchers showed that a blood test for thyroid cancer can detect persistent or recurrent disease even before doctors can find any trace of a tumor.  The test uses a relatively new drug called thyrotropinal alfa, or Thyrogen, to allow thyroglobulin testing without the debilitating side effects that sometimes accompany the test.
  • Clinical tests conducted by Manisha Shah, MD, Matthew Ringel, MD, and colleagues at the OSU CCC-James are evaluating two new treatment options:  1) a compound known as BAY 43-9006, a new targeted therapy designed to attack advanced thyroid cancer at its molecular roots, and 2) the popular pain reliever Celebrex as a treatment for metastatic thyroid cancer.
  • A study by OSU CCC-James researchers showed how genetic differences could help distinguish two closely related types of cancer:  papillary thyroid carcinoma and follicular thyroid carcinoma.  Distinguishing between the two cancers is important because the malignancies behave differently and may require different treatment.

Recent publications by endocrine cancer researchers at the OSU CCC-James include:

Richard Kloos, MD

  • Long-Term Follow-Up Studies of Thyroid Carcinoma

Matthew Ringel, MD

  • Diagnostic Molecular Markers in Thyroid Cancer
  • BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

Lawrence Kirschner, MD, PhD

  • A Mouse Model for the Carney Complex Tumor Syndrome Develops Neoplasia in Cyclic AMP-Responsive Tissues
  • A Mouse Model for Carney Complex

Albert de la Chapelle, MD, PhD

  • Allelic Variation in Gene Expression in Thyroid Tissue
  • Expression Profiling of Papillary Thyroid Cancer

Sissy Jhiang, PhD

  • Studies of NIS Expression in Thyroid Cancer Cell Lines and Use in Imaging
  • Studies of RET-PTC1 Function in Thyroid Tumorigenesis

Ching-Shih Chen, PhD

  • Development of New Therapetuic Agents Active Against Thyroid Cancer Cells (with Ringel)

William Farrar, MD

  • Psychological Responses to Cancer Recurrence
  • Thyroid Carcinoma

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: